Objective:To observe the effects of Lifei tabled on the stable phase of bronchial asthma , and to study the intervention effects on matrix metalloproteinases 9 (matrix metalloprotein-MMP of 9) concentration.Methods:A total of 60 patients with bron-chial in the stable phase who treated in our hospital included into the study , were randomly divided into the control group and the observation group , with 30 cases in each group .Two groups of patients both received aminophylline tablets , 0.1 g/time, 3 times/day.The observation group had Lifei tables based on the treatment on the basic treatment , 2 tablets/times, 3 times/day.Both groups had 20 days for a course of treatment .After treatment , TCM syndrome integrals , pulmonary function , asthma indexes and the changes of serum concentration of MMP -9 of two groups were compared .Results:1) The single and general TCM syndrome integrals decreased in the two groups of patients than before treatment (P<0.05), and the improvement of the observation group was more significantly (P<0.05);2) The clinical total effective rate of the observation group was 90％, and 76.66％in the con-trol group.The differences were with statistically significant (P<0.05);3) The recovery time of patients with asthma in the ob-servation group was shortened than the control group , with statistically significant differences ( P<0.05 );4 ) forced expiratory volume (FEVl), peak expiratory flow (PEF) and 1st second forced expiratory lung forced vital capacity (FEVl/FVC) improved in the two groups after treatment (P<0.05), and the improved trend of the observation group was more obvious .The control group were with statistically significant differences (P<0.05);5) Detected by ELISA test, MMP-9 levels decreased after treatment in the two groups of children , and the observation group had lower levels of MMP-9 after treatment compared with the control group (P<0.05).Conclusion:Based on conventional treatment , the Lifei tablets can further relieve state of bronchial asthma , with high safety, which is recommended in the clinical application .%目的:观察利肺片治疗稳定期支气管哮喘的效果,并研究其对基质金属蛋白酶-9(Matrix Metalloprotein-9,MMP-9)的干预效应.方法:选取2015年1月至2016年12月支气管稳定期患者60例,随机分为对照组和观察组,每组30例.2组患者均接受口服氨茶碱片,0.1 g/次,3次/d.观察组在此治疗基础上加用利肺片,2片/次,3次/d,2组均以20 d为1个疗程,疗程结束后比较2组患者中医证候积分、肺功能、哮喘指标复常时间以及血清MMP-9.结果:2组单项及总的中医证候积分均较治疗前下降(P<0.05),观察组改善更明显(P<0.05);观察组临床总有效率90.00％,对照组临床总有效率76.66％,差异有统计学意义(P<0.05);3观察组患者哮喘指标的复常时间较对照组缩短,差异有统计学意义(P<0.05);2组治疗后第1秒用力呼气肺容积(FEV1)、呼气峰流量(PEF)及第1秒用力呼气容积/用力肺活量(FEV1/FVC)均较治疗前改善(P<0.05),其中观察组改善得趋势更明显,与对照组比较,差异有统计学意义(P<0.05);2组治疗后MMP-9水平有所下降,与对照组比较,观察组治疗后MMP-9水平更低(P<0.05).结论:常规治疗基础上,利肺片可进一步缓解支气管哮喘病情,安全性高.
展开▼
